{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:21:14Z","timestamp":1780381274079,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI132348"],"award-info":[{"award-number":["AI132348"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00052"],"award-info":[{"award-number":["75N93019C00052"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaip.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T08:33:48Z","timestamp":1629275628000},"page":"3599-3603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Update on Influenza Vaccines: Needs and Progress"],"prefix":"10.1016","volume":"9","author":[{"given":"Richard B.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna G.","family":"Ovsyannikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Poland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.08.003_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6908a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season","volume":"69","author":"Grohskopf","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaip.2021.08.003_bib4","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1016\/j.vaccine.2021.03.079","article-title":"Safety of vaccines used for routine immunization in the United States: an updated systematic review and meta-analysis","volume":"39","author":"Gidengil","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2021.08.003_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6803a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season","volume":"68","author":"Grohskopf","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaip.2021.08.003_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.chom.2019.04.013","article-title":"Preventing an antigenically disruptive mutation in egg-based H3N2 seasonal influenza vaccines by mutational incompatibility","volume":"25","author":"Wu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jaip.2021.08.003_bib7","article-title":"Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing","volume":"8","author":"Rajaram","year":"2020","journal-title":"Ther Adv Vaccines Immunother"},{"key":"10.1016\/j.jaip.2021.08.003_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.vaccine.2016.12.011","article-title":"Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis","volume":"35","author":"Domnich","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2021.08.003_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.coph.2018.03.014","article-title":"Adjuvant strategies to improve vaccination of the elderly population","volume":"41","author":"Weinberger","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jaip.2021.08.003_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/21645515.2017.1423153","article-title":"Influenza vaccines: evaluation of the safety profile","volume":"14","author":"Trombetta","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaip.2021.08.003_bib11","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1473-3099(20)30130-4","article-title":"The state of vaccine safety science: systematic reviews of the evidence","volume":"20","author":"Dudley","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaip.2021.08.003_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaip.2021.08.003_bib13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barre syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"Kwong","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaip.2021.08.003_bib14","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2021.08.003_bib15","doi-asserted-by":"crossref","first-page":"f794","DOI":"10.1136\/bmj.f794","article-title":"Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine: retrospective analysis","volume":"346","author":"Miller","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2021.08.003_bib16","doi-asserted-by":"crossref","first-page":"e114361","DOI":"10.1371\/journal.pone.0114361","article-title":"Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk","volume":"9","author":"Vaarala","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2021.08.003_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/INF.0b013e3181a6a511","article-title":"Adversomics: the emerging field of vaccine adverse event immunogenetics","volume":"28","author":"Poland","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaip.2021.08.003_bib18","article-title":"Influenza vaccines: past, present, and future","author":"Kim","year":"2021","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jaip.2021.08.003_bib19","first-page":"E115","article-title":"History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines","volume":"57","author":"Barberis","year":"2016","journal-title":"J\u00a0Prev Med Hyg"},{"key":"10.1016\/j.jaip.2021.08.003_bib20","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2021.08.003_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.15585\/mmwr.mm6907a1","article-title":"Interim estimates of 2019-20 seasonal influenza vaccine effectiveness\u2014United States, February 2020","volume":"69","author":"Dawood","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaip.2021.08.003_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2017.02.009","article-title":"Universal influenza virus vaccines and therapeutic antibodies","volume":"23","author":"Nachbagauer","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaip.2021.08.003_bib24","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/v12101186","article-title":"A\u00a0decade in review: a systematic review of universal influenza vaccines in clinical trials during the 2010 decade","volume":"12","author":"Corder","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jaip.2021.08.003_bib25","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1016\/j.vaccine.2020.09.062","article-title":"Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model","volume":"39","author":"Guilfoyle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2021.08.003_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/vaccines9050452","article-title":"Construction and immunogenicity of modified mRNA-vaccine variants encoding influenza virus antigens","volume":"9","author":"Starostina","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jaip.2021.08.003_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1086\/649428","article-title":"A\u00a0novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1","volume":"201","author":"Wacheck","year":"2021","journal-title":"Infect Dis"},{"key":"10.1016\/j.jaip.2021.08.003_bib29","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.vaccine.2014.02.009","article-title":"Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans","volume":"32","author":"Morokutti","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2021.08.003_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/vaccines7010033","article-title":"Safety and immunogenicity of the heterosubtypic influenza A vaccine MVA-NP+M1 manufactured on the AGE1.CR.pIX avian cell line","volume":"7","author":"Folegatti","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jaip.2021.08.003_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2020.607333","article-title":"Adenoviral vectors as vaccines for emerging avian influenza viruses","volume":"11","author":"Kerstetter","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.08.003_bib32","doi-asserted-by":"crossref","first-page":"e140794","DOI":"10.1172\/JCI140794","article-title":"A\u00a0replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity","volume":"131","author":"Matsuda","year":"2021","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.jaip.2021.08.003_bib33","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1016\/j.vaccine.2021.06.072","article-title":"Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice","volume":"39","author":"Lo","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jaip.2021.08.003_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41541-019-0155-z","article-title":"A\u00a0single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades","volume":"5","author":"Furuyama","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jaip.2021.08.003_bib35","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaip.2021.08.003_bib36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaip.2021.08.003_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41467-017-02725-4","article-title":"Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses","volume":"9","author":"Deng","year":"2018","journal-title":"Nat Commun"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821009028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821009028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:30:18Z","timestamp":1761975018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821009028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2213219821009028"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.08.003","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Influenza Vaccines: Needs and Progress","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}